Prystupa, Katsiaryna
Delgado, Graciela E.
Moissl, Angela P.
Kleber, Marcus E.
Birkenfeld, Andreas L.
Heni, Martin
Fritsche, Andreas
März, Winfried
Wagner, Robert
Funding for this research was provided by:
Deutsches Diabetes-Zentrum (DDZ)
Article History
Received: 9 February 2023
Accepted: 14 July 2023
First Online: 17 August 2023
Declarations
:
: Outside of the current work, R.W. does report lecture fees from Novo Nordisk and travel grants from Eli Lilly. He served on the advisory board of Akcea Therapeutics. In addition to his current work, A.L.B reports lecture fees from AstraZeneca, Boehringer Ingelheim, and NovoNordisk. He served on advisory boards of AstraZeneca, Boehringer Ingelheim and NovoNordisk. Outside of the current work, A.F. reports lecture fees and advisory board membership from Sanofi, Novo Nordisk, Eli Lilly, Boehringer Ingelheim and AstraZeneca. Outside of the current work, M.H. reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tübingen), advisory board for Boehringer Ingelheim, and lecture fees from Boehringer Ingelheim, Sanofi, Novo Nordisk, and Eli Lilly. None of the other authors report a conflict of interest.
: The study protocol had been approved by the local institutional review board (Ethics committee of the Landesärztekammer Rheinland-Pfalz, No. 1997 − 203). The study was performed in adherence to the principles of the Declaration of Helsinki. All volunteers provided written informed consent to participate in the study.
: Not applicable.